No Data
Soiken Holdings: Confirmation
Soiken Holdings Sees FY Loss Y450.00M
Soiken Holdings 1H Loss Y222.00M Vs Loss Y487.00M
Soiken Holdings: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/6 [Japanese GAAP] (consolidated)
Hot Stocks Digest (Morning Session): Mercari, Nichicon, TOWA, ETC.
A significant decline.
Sōi Ken - Soars, subsidiary obtains a patent related to new technology using lactoferrin in collaboration with Varinos.
Soaring. After the close of trading on the 6th, it was announced that NRL Pharma, a subsidiary, obtained a patent in collaboration with Varinos for a new technology using lactoferrin, which is viewed positively. The technology aims to improve the chances of pregnancy for infertility patients through the enhancement of intrauterine flora, which is part of a joint patent previously held by NRL Pharma and Varinos. Additionally, a technology to mitigate the risks of miscarriage and preterm birth caused by disruptions in the intrauterine microbiota after pregnancy has been added to the same patent.
